[{"address1": "333 Las Olas Way", "address2": "CU4 Suite 433", "city": "Fort Lauderdale", "state": "FL", "zip": "33301", "country": "United States", "phone": "954-515-0810", "website": "https://sunshinebiopharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Dr. Steve N. Slilaty Ph.D.", "age": 72, "title": "Chairman, President & CEO", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 640000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Camille  Sebaaly", "age": 65, "title": "CFO & Secretary", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 695000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Abderrazzak  Merzouki", "age": 60, "title": "Chief Science Officer & Director", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 340000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Malek  Chamoun", "age": 39, "title": "Chief Development Officer", "yearBorn": 1985, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.83, "open": 2.83, "dayLow": 2.805, "dayHigh": 2.9093, "regularMarketPreviousClose": 2.83, "regularMarketOpen": 2.83, "regularMarketDayLow": 2.805, "regularMarketDayHigh": 2.9093, "beta": -1.036, "forwardPE": 0.014507508, "volume": 35554, "regularMarketVolume": 35554, "averageVolume": 718165, "averageVolume10days": 178390, "averageDailyVolume10Day": 178390, "bid": 2.81, "ask": 2.94, "bidSize": 100, "askSize": 100, "marketCap": 7850394, "fiftyTwoWeekLow": 2.106, "fiftyTwoWeekHigh": 572.0, "priceToSalesTrailing12Months": 0.2381831, "fiftyDayAverage": 2.8101, "twoHundredDayAverage": 16.380356, "currency": "USD", "enterpriseValue": -5840889, "profitMargins": -0.12821999, "floatShares": 1997620, "sharesOutstanding": 2708340, "sharesShort": 217917, "sharesShortPriorMonth": 555634, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.109, "heldPercentInsiders": 0.00234, "heldPercentInstitutions": 0.01843, "shortRatio": 0.57, "shortPercentOfFloat": 0.1091, "impliedSharesOutstanding": 2708340, "bookValue": 12.515, "priceToBook": 0.23161007, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -4225928, "trailingEps": -127.9, "forwardEps": 199.8, "lastSplitFactor": "1:20", "lastSplitDate": 1723075200, "enterpriseToRevenue": -0.177, "enterpriseToEbitda": 1.227, "52WeekChange": -0.99382097, "SandP52WeekChange": 0.22408533, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SBFM", "underlyingSymbol": "SBFM", "shortName": "Sunshine Biopharma Inc.", "longName": "Sunshine Biopharma, Inc.", "firstTradeDateEpochUtc": 1644935400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "7909c686-ce8d-3dd2-8c10-62221258e4a3", "messageBoardId": "finmb_78729055", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.8986, "targetHighPrice": 300.0, "targetLowPrice": 300.0, "targetMeanPrice": 300.0, "targetMedianPrice": 300.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 12206655, "totalCashPerShare": 6.104, "ebitda": -4761139, "totalDebt": 556551, "quickRatio": 3.406, "currentRatio": 5.737, "totalRevenue": 32959492, "debtToEquity": 2.223, "revenuePerShare": 197.42, "returnOnAssets": -0.10747, "returnOnEquity": -0.17982, "grossProfits": 10144791, "freeCashflow": -12837234, "operatingCashflow": -11813574, "revenueGrowth": 0.416, "grossMargins": 0.3078, "ebitdaMargins": -0.14445, "operatingMargins": -0.13116, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-18"}]